A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: Budesonide/formoterol (SYMBICORT) pMDI; Drug: Budesonide HFA pMDI

Study type: Interventional

Funder types: Industry

Identifiers

NCT00419952

D5896C00022

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.

Enrollment: 742 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female, African American (self-reported), ≥12 years of age
• Moderate to severe asthma requiring treatment with an inhaled corticosteroid
• Diagnosis of asthma for at least 6 months

Exclusion criteria

• Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
• Any significant disease or disorder that may jeopardize a subject's safety

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

742 participants in 2 patient groups

Symbicort

Experimental group

Description:

Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)

Treatment:

Drug: Budesonide/formoterol (SYMBICORT) pMDI

Budesonide

Experimental group

Description:

Budesonide HFA pMDI 160 ug x 2 actuations BID

Treatment:

Drug: Budesonide HFA pMDI